Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: A randomized, double-blind, placebo-controlled trial

Journal of Clinical Oncology

Volumn 29, Issue 29, 2011, Pages 3862-3868

  Boekhout, Annelies H ^a   Vincent, Andrew D ^a   Dalesio, Otilia B ^a   Van Den Bosch, Joan ^c   Foekema Töns, Joke H ^a   Adriaansz, Sandra ^a   Sprangers, Sylvia ^c   Nuijen, Bastiaan ^b   Beijnen, Jos H ^a,b,d   Schellens, Jan H M ^a,d  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b SLOTERVAART HOSPITAL   (Netherlands)

^c ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CLONIDINE; GOSERELIN; PLACEBO; TAMOXIFEN; VENLAFAXINE;

ADULT; AGED; ANXIETY; ARTICLE; BREAST CANCER; CONSTIPATION; CONTROLLED STUDY; DECREASED APPETITE; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ENURESIS; HOT FLUSH; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEXUAL FUNCTION; SIDE EFFECT; SLEEP QUALITY; SOMNOLENCE; SWEATING; TREATMENT DURATION; TREATMENT RESPONSE; XEROSTOMIA;

ADULT; AGED; ANALGESICS; BREAST NEOPLASMS; CLONIDINE; CYCLOHEXANOLS; DOUBLE-BLIND METHOD; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; PLACEBOS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 80053974505     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.33.1298     Document Type: Article

References (35)

1. Mar Fan HG, Houédé -Tchen N, Chemerynsky I, et al: Menopausal symptoms in women undergoing chemotherapy-induced and natural menopause: A prospective controlled study. Ann Oncol 21:983-987, 2010
2. Couzi RJ, Helzlsouer KJ, Fetting JH: Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 13:2737-2744, 1995
3. Fallowfield L, Fleissig A, Edwards R, et al: Tamoxifen for the prevention of breast cancer: Psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 19:1885-1892, 2001
4. Ganz PA: Impact of tamoxifen adjuvant therapy on symptoms, functioning, and quality of life. J Natl Cancer Inst Monogr 30:130-134, 2001
5. Savard MH, Savard J, Quesnel C, et al: The influence of breast cancer treatment on the occurrence of hot flashes. J Pain Symptom Manage 37:687-697, 2009
6. Partridge AH, Avorn J, Wang PS, et al: Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 94:652-661, 2002 (Pubitemid 34552485)
7. Hershman DL, Shao T, Kushi LH, et al: Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126:529-537, 2011
8. Geiger AM, Thwin SS, Lash TL, et al: Recurrences and second primary breast cancers in older women with initial early-stage disease. Cancer 109:966-974, 2007 (Pubitemid 46333538)
9. McCowan C, Shearer J, Donnan PT, et al: Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99:1763-1768, 2008
10. Shanafelt TD, Barton DL, Adjei AA, et al: Pathophysiology and treatment of hot flashes. Mayo Clin Proc 77:1207-1218, 2002 (Pubitemid 35266369)
11. Stearns V, Johnson MD, Rae JM, et al: Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst 95:1758-1764, 2003 (Pubitemid 38008898)
12. Freedman RR: Hot flashes: Behavioral treatments, mechanisms, and relation to sleep. Am J Med 118:124-130, 2005 (suppl 12B)
13. Barton DL, LaVasseur BI, Sloan JA, et al: Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 28:3278-3283, 2010
14. Loprinzi CL, Sloan JA, Perez EA, et al: Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 20:1578-1583, 2002 (Pubitemid 34260538)
15. Loprinzi CL, Qin R, Balcueva EP, et al: Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol 28:641-647, 2010
16. Pandya KJ, Morrow GR, Roscoe JA, et al: Gabapentin for hot flashes in 420 women with breast cancer: A randomised double-blind placebo-controlled trial. Lancet 366:818-824, 2005 (Pubitemid 41557381)
17. Jin Y, Desta Z, Stearns V, et al: CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-39, 2005
18. Leyland-Jones B, Regan MM, Bouzyk M, et al: Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial. San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2010 (abstr S1-8)
19. Rae JM, Drury S, Hayes DF, et al: Lack of correlation between gene variants in tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial. San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-10, 2010 (abstr S1-7)
20. Loprinzi CL, Kugler JW, Sloan JA, et al: Venlafaxine in management of hot flashes in survivors of breast cancer: A randomised controlled trial. Lancet 356:2059-2063, 2000 (Pubitemid 32009821)
21. Goldberg RM, Loprinzi CL, O'Fallon JR, et al: Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 12:155-158, 1994 (Pubitemid 24020635)
22. Pandya KJ, Raubertas RF, Flynn PJ, et al: Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: A University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 132:788-793, 2000 (Pubitemid 30317793)
23. North American Menopause Society: Treatment of menopause-associated vasomotor symptoms: Position statement of The North American Menopause Society. Menopause 11:11-33, 2004
24. Hickey M, Saunders C, Partridge A, et al: Practical clinical guidelines for assessing and managing menopausal symptoms after breast cancer. Ann Oncol 19:1669-1680, 2008
25. Sloan JA, Loprinzi CL, Novotny PJ, et al: Methodologic lessons learned from hot flash studies. J Clin Oncol 19:4280-4290, 2001 (Pubitemid 33096775)
26. de Weerd A, de Haas S, Otte A, et al: Subjective sleep disturbance in patients with partial epilepsy: A questionnaire-based study on prevalence and impact on quality of life. Epilepsia 45:1397-1404, 2004 (Pubitemid 39470044)
27. Rodgers J, Martin CR, Morse RC, et al: An investigation into the psychometric properties of the Hospital Anxiety and Depression Scale in patients with breast cancer. Health Qual Life Outcomes 3:41, 2005
28. Thirlaway K, Fallowfield L, Cuzick J: The Sexual Activity Questionnaire: A measure of women's sexual functioning. Qual Life Res 5:81-90, 1996 (Pubitemid 26100506)
29. Stead ML, Crocombe WD, Fallowfield LJ, et al: Sexual activity questionnaires in clinical trials: Acceptability to patients with gynaecological disorders. Br J Obstet Gynaecol 106:50-54, 1999 (Pubitemid 29041975)
30. Division of Metabolism and Endocrine Drug Products: Guidance for Clinical Evaluation of Combination Estrogen/Progestin-Containing Drug Products Used for Hormone Replacement Therapy of Postmenopausal Women. http://www.fda.gov/ohrms/ dockets/ac/99/backgrd/3557b1f.pdf
31. Loprinzi CL, Diekmann B, Novotny PJ, et al: Newer antidepressants and gabapentin for hot flashes: A discussion of trial duration. Menopause 16:883-887, 2009
32. Loibl S, Schwedler K, von Minckwitz G, et al: Venlafaxine is superior to clonidine as treatment of hot flashes in breast cancer patients: A double-blind, randomized study. Ann Oncol 18:689-693, 2007 (Pubitemid 46523272)
33. Buijs C, Mom CH, Willemse PH, et al: Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: A double-blind, randomized cross-over study. Breast Cancer Res Treat 115:573-580, 2009
34. Gregorian RS, Golden KA, Bahce A, et al: Antidepressant-induced sexual dysfunction. Ann Pharmacother 36:1577-1589, 2002
35. Carpenter JS, Storniolo AM, Johns S, et al: Randomized, double-blind, placebo-controlled cross-over trials of venlafaxine for hot flashes after breast cancer. Oncologist 12:124-135, 2007 (Pubitemid 46150798)